



UNODC
United Nations Office on Drugs and Crime



1 EXECUTIVE SUMMARY
IMPACT OF COVID-19
POLICY IMPLICATIONS

WORLD
2020 **DRUG**
REPORT

© United Nations, June 2020. All rights reserved worldwide.
ISBN: 978-92-1-148345-1
eISBN: 978-92-1-005047-0
United Nations publication, Sales No. E.20.XI.6

This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source.

Suggested citation:

World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6).

No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC.

DISCLAIMER

The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement.

Comments on the report are welcome and can be sent to:

Division for Policy Analysis and Public Affairs
United Nations Office on Drugs and Crime
PO Box 500
1400 Vienna
Austria
Tel: (+43) 1 26060 0
Fax: (+43) 1 26060 5827

E-mail: wdr@un.org

Website: www.unodc.org/wdr2020

PREFACE

This is a time for science and solidarity, as United Nations Secretary-General António Guterres has said, highlighting the importance of trust in science and of working together to respond to the global COVID-19 pandemic.

The same holds true for our responses to the world drug problem. To be effective, balanced solutions to drug demand and supply must be rooted in evidence and shared responsibility. This is more important than ever, as illicit drug challenges become increasingly complex, and the COVID-19 crisis and economic downturn threaten to worsen their impacts, on the poor, marginalized and vulnerable most of all.

Some 35.6 million people suffer from drug use disorders globally. While more people use drugs in developed countries than in developing countries, and wealthier segments of society have a higher prevalence of drug use, people who are socially and economically disadvantaged are more likely to develop drug use disorders.

Only one out of eight people who need drug-related treatment receive it. While one out of three drug users is a woman, only one out of five people in treatment is a woman. People in prison settings, minorities, immigrants and displaced people also face barriers to treatment due to discrimination and stigma. Of the 11 million people who inject drugs, half of them are living with hepatitis C, and 1.4 million with HIV.

Around 269 million people used drugs in 2018, up 30 per cent from 2009, with adolescents and young adults accounting for the largest share of users. More people are using drugs, and there are more drugs, and more types of drugs, than ever.

Seizures of amphetamines quadrupled between 2009 and 2018. Even as precursor control improves globally, traffickers and manufacturers are using designer chemicals, devised to circumvent international controls, to synthesize amphetamine, methamphetamine and ecstasy. Production of heroin and cocaine remain among the highest levels recorded in modern times.

The growth in global drug supply and demand poses challenges to law enforcement, compounds health risks and complicates efforts to prevent and treat drug use disorders.

At the same time, more than 80% of the world's population, mostly living in low- and middle-income

countries, are deprived of access to controlled drugs for pain relief and other essential medical uses.

Governments have repeatedly pledged to work together to address the many challenges posed by the world drug problem, as part of commitments to achieve the Sustainable Development Goals, and most recently in the 2019 Ministerial Declaration adopted by the Commission on Narcotic Drugs (CND). But data indicates that development assistance to address drug control has actually fallen over time.


Balanced, comprehensive and effective responses to drugs depend on governments to live up to their promises, and provide support to leave no one behind.

Health-centred, rights-based and gender-responsive approaches to drug use and related diseases deliver better public health outcomes. We need to do more to share this learning and support implementation, most of all in developing countries, including by strengthening cooperation with civil society and youth organizations.

The international community has an agreed legal framework and the commitments outlined in the 2019 CND Ministerial Declaration. The United Nations Office on Drugs and Crime (UNODC) provides integrated support to build national capacities and strengthen international cooperation to turn pledges into effective action on the ground.

The theme for this year's International Day against Drug Abuse and Illicit Trafficking, "Better Knowledge for Better Care", highlights the importance of scientific evidence to strengthen responses to the world drug problem and support the people who need us. It also speaks to the ultimate goal of drug control, namely the health and welfare of humankind. Through learning and understanding we find compassion and seek solutions in solidarity.

It is in this spirit that I present the UNODC *World Drug Report 2020*, and I urge governments and all stakeholders to make the best use of this resource.



Ghada Waly
Executive Director
United Nations Office on Drugs and Crime

Acknowledgements

The *World Drug Report 2020* was prepared by the Research and Trend Analysis Branch, Division for Policy Analysis and Public Affairs, United Nations Office on Drugs and Crime (UNODC), under the supervision of Jean-Luc Lemahieu, Director of the Division, and Angela Me, Chief of the Research and Trend Analysis Branch, and the coordination of Chloé Carpentier, Chief of the Drug Research Section.

Content overview

Chloé Carpentier
Angela Me

Francesca Rosa
Ali Saadeddin
Keith Sabin (UNAIDS)
Antoine Vella

Analysis and drafting

Andrada-Maria Filip
Jaqueline Garcia-Yi
Karin Haar
Barbara Hastie (Indiana University)
Maria Melchior
Kamran Niaz
Thomas Pietschmann
Sascha Strupp
Irmgard Zeiler

Mapping
Antero Keskinen
Francesca Massanello
Deniz Mermerci
Irina Tsoy
Lorenzo Vita

Editing

Joseph Boyle
Jonathan Gibbons

Data management and estimate production

Sonia Arias Garcia (UNAIDS)
Tsegahiwot Belachew
Enrico Bisogno
Diana Camerini
Conor Crean
Hernan Epstein
Riku Lehtovuori
Sabrina Levissianos
Virginia Macdonald (WHO)
Andrea Oterová
Umidjon Rakhmonberdiyev
Martin Raitelhuber

Graphic design and production

Anja Korenblik
Suzanne Kunnen
Kristina Kuttinig
Federica Martinelli

Data support

Natalia Ivanova
Lisa Weijler

Administrative support

Andrada-Maria Filip
Iulia Lazar

Review and comments

The *World Drug Report 2020* benefited from the expertise of and invaluable contributions from UNODC colleagues in all divisions.

The Research and Trend Analysis Branch acknowledges the invaluable contributions and advice provided by the *World Drug Report* Scientific Advisory Committee:

Jonathan Caulkins
Paul Griffiths
Marya Hynes
Vicknasingam B. Kasinather
Charles Parry

Afarin Rahimi-Movaghar
Peter Reuter
Alison Ritter
Francisco Thoumi

The research and production of the joint UNODC/UNAIDS/WHO/World Bank estimates of the number of people who inject drugs in Booklet 2 were funded by the HIV/AIDS Section of the Drug Prevention and Health Branch of the Division for Operations of UNODC.

The analysis on purchases of drugs on the darknet in Booklet 4 is based on original data graciously shared by the *Global Drug Survey team*.

The research for booklet 5 benefitted from the support of the Informal International Scientific Network to the Commission on Narcotic Drugs, as well as of the Prevention, Treatment and Rehabilitation Section of the Drug Prevention and Health Branch of the Division for Operations of UNODC, which also funded it.

The analysis on access to controlled medicines in Booklet 6 is based on original data graciously shared by INCB and benefitted from the contribution of the Walther Center in Global Palliative Care of the University of Indiana.

CONTENTS

BOOKLET 1 EXECUTIVE SUMMARY, IMPACT OF COVID-19, POLICY IMPLICATIONS

- PREFACE 1
- EXPLANATORY NOTES 5
- EXECUTIVE SUMMARY 7
 - EFFECTS OF COVID-19 ON DRUG MARKETS 7
 - Impact could be like the 2008 economic crisis*..... 7
- EXPANSION AND COMPLEXITY 7
 - Market growth*..... 7
 - Increased complexity* 11
 - Rapid market changes* 13
 - Policy changes and changing trends* 13
 - Disadvantaged face harm from legal and illicit drug markets*..... 14
- LATEST TRENDS..... 17
 - Drug use* 17
 - Supply chains* 18
- RESPONSE TO THE DRUG PROBLEM STILL INADEQUATE 20
- COVID-19 AND THE DRUG SUPPLY CHAIN: FROM PRODUCTION AND TRAFFICKING TO USE 23
 - Measures implemented to prevent the spread of COVID-19 are having a mixed impact on the drug supply chain*..... 23
- IMPACT OF COVID-19..... 23
 - Drug production*..... 24
 - Drug trafficking* 25
 - Drug use* 27
 - Addressing the global drug problem requires drug policy implemented in tandem with broader agendas for sustainable development, security and human rights* 29
- POLICY IMPLICATIONS..... 29
 - Mainstream evidence-based prevention of drug use and treatment of drug use disorders and the delivery of services aimed at reducing the associated harm in community settings are required*..... 30
 - The disparity in the access to and availability of controlled substances for pain management and palliative care needs to be addressed*..... 31
 - Alternative development initiatives need to avoid generalizations if they are to enhance farmers' livelihoods and reductions in illicit crop cultivation areas*..... 32
 - The distinctive needs of women have to be addressed if the particular vulnerability of those in contact with the criminal justice system for drug-related offences is to be reduced*..... 32
 - The cannabis market needs to be monitored closely*..... 33
 - Enhanced understanding of international cooperation is necessary to address the transnational nature of the drug problem*..... 34

Further research is needed to improve understanding of the complexities of drug markets, including on the impact of COVID-1934

ANNEX.....	37
GLOSSARY	57
REGIONAL GROUPINGS	59

BOOKLET 2	DRUG USE AND HEALTH CONSEQUENCES
BOOKLET 3	DRUG SUPPLY
BOOKLET 4	CROSS-CUTTING ISSUES: EVOLVING TRENDS AND NEW CHALLENGES
BOOKLET 5	SOCIOECONOMIC CHARACTERISTICS AND DRUG USE DISORDERS
BOOKLET 6	OTHER DRUG POLICY ISSUES

EXPLANATORY NOTES

The designations employed and the presentation of the material in the *World Drug Report* do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Countries and areas are referred to by the names that were in official use at the time the relevant data were collected.

Since there is some scientific and legal ambiguity about the distinctions between “drug use”, “drug misuse” and “drug abuse”, the neutral term “drug use” is used in the *World Drug Report*. The term “misuse” is used only to denote the non-medical use of prescription drugs.

All uses of the word “drug” and the term “drug use” in the *World Drug Report* refer to substances controlled under the international drug control conventions, and their non-medical use.

All analysis contained in the *World Drug Report* is based on the official data submitted by Member States to the UNODC through the annual report questionnaire unless indicated otherwise.

The data on population used in the *World Drug Report* are taken from: *World Population Prospects: The 2019 Revision* (United Nations, Department of Economic and Social Affairs, Population Division).

References to dollars (\$) are to United States dollars, unless otherwise stated.

References to tons are to metric tons, unless otherwise stated.

The following abbreviations have been used in the present booklet:

AIDS	acquired immunodeficiency syndrome
<i>alpha</i> -PVP	<i>alpha</i> -pyrrolidinovalerophenone
APAA	<i>alpha</i> -phenylacetoacetamide
APAAN	<i>alpha</i> -phenylacetoacetonitrile
ATS	amphetamine-type stimulant
CBD	cannabidiol
COVID-19	coronavirus disease
DALYs	disability-adjusted life years
EMCDDA	European Monitoring Centre for Drugs and Drug Addiction
HIV	human immunodeficiency virus
INCB	International Narcotics Control Board
MAPA	methyl <i>alpha</i> -phenylacetoacetate
NPS	new psychoactive substances
P-2-P	1-phenyl-2-propanone
THC	Δ -9 – tetrahydrocannabinol
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNODC	United Nations Office on Drugs and Crime
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_11282

